{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:02:24Z","timestamp":1787029344990,"version":"build-2736575974"},"reference-count":80,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Natural Science Foundation of China","award":["81970698"],"award-info":[{"award-number":["81970698"]}]},{"name":"National Natural Science Foundation of China","award":["81970708"],"award-info":[{"award-number":["81970708"]}]},{"name":"National Natural Science Foundation of China","award":["7202216"],"award-info":[{"award-number":["7202216"]}]},{"name":"Beijing Natural Science Foundation","award":["81970698"],"award-info":[{"award-number":["81970698"]}]},{"name":"Beijing Natural Science Foundation","award":["81970708"],"award-info":[{"award-number":["81970708"]}]},{"name":"Beijing Natural Science Foundation","award":["7202216"],"award-info":[{"award-number":["7202216"]}]},{"name":"National Natural Science Foundation of China","award":["81970698"],"award-info":[{"award-number":["81970698"]}]},{"name":"National Natural Science Foundation of China","award":["81970708"],"award-info":[{"award-number":["81970708"]}]},{"name":"National Natural Science Foundation of China","award":["7202216"],"award-info":[{"award-number":["7202216"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background: Proprotein convertase subtilisin\/kexin type 9 inhibitor (PCSK9i) has been reported to exhibit anti-neoplasm effects. However, the specific impacts remain uncertain. This study aims to evaluate the association between PCSK9i and the risk of neoplasm. Methods: Randomized controlled trials (RCTs) comparing PCSK9i with other lipid-lowering drugs or placebo in patients, which reported neoplasm events, were included. Data were sourced from PubMed, Embase, Web of Science, the Cochrane Central Register of Controlled Trials, and the Clinicaltrial.gov website from the inception to June 2024. The primary endpoint was the association between PCSK9i and the risk of overall neoplasm events. Results: A total of 37 RCTs with 108,430 participants were included. PCSK9i treatment was associated with a lower risk of neoplasm compared to non-users (RR = 0.92, 95% CI, 0.85 to 0.99, I2 = 0%). Subgroup analysis revealed a more prominent risk reduction of overall neoplasm in studies with female-dominant populations (male percentage &lt; 50%, RR = 0.47, 95% CI, 0.27 to 0.82, I2 = 0%), with a significant subgroup differences (p = 0.02). Meta-regression analysis also suggested that the lower percentage of males was associated with a decreased risk of neoplasms (\u03b2 = 0.018, 95% CI, 0.0063, 0.031, p = 0.002). Meanwhile, the decreased risk of neoplasms was independent of LDL-c reduction. Conclusions: PCSK9i therapy was associated with reduced risk of overall neoplasm, especially in female-dominant populations. The benefits for lower risk of neoplasm with PCSK9i treatment were independent of LDL-c reduction.<\/jats:p>","DOI":"10.3390\/ph18081095","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T07:54:26Z","timestamp":1753343666000},"page":"1095","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["PCSK9 Inhibitor and Potential Decreased Risk of Neoplasms, Especially in Females: A Meta-Analysis"],"prefix":"10.3390","volume":"18","author":[{"given":"Tingyang","family":"Wei","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, Peking University People\u2019s Hospital, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zonglin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Peking University People\u2019s Hospital, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chu","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Peking University People\u2019s Hospital, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuteng","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Peking University People\u2019s Hospital, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changjie","family":"Tie","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Peking University People\u2019s Hospital, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7881-0543","authenticated-orcid":false,"given":"Xiaoling","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Peking University People\u2019s Hospital, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Peking University People\u2019s Hospital, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjia","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Peking University People\u2019s Hospital, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linong","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Peking University People\u2019s Hospital, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e069066","DOI":"10.1136\/bmj-2021-069066","article-title":"PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: A clinical practice guideline with risk-stratified recommendations","volume":"377","author":"Hao","year":"2022","journal-title":"Bmj"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e069116","DOI":"10.1136\/bmj-2021-069116","article-title":"PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: A systematic review and network meta-analysis","volume":"377","author":"Khan","year":"2022","journal-title":"Bmj"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"531","DOI":"10.7150\/thno.80289","article-title":"SIRT3 mediates the effects of PCSK9 inhibitors on inflammation, autophagy, and oxidative stress in endothelial cells","volume":"13","author":"Prattichizzo","year":"2023","journal-title":"Theranostics"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Mahboobnia, K., Pirro, M., Marini, E., Grignani, F., Bezsonov, E.E., Jamialahmadi, T., and Sahebkar, A. (2021). PCSK9 and cancer: Rethinking the link. Biomed. Pharmacother., 140.","DOI":"10.1016\/j.biopha.2021.111758"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e38010","DOI":"10.1097\/MD.0000000000038010","article-title":"Causal association between lipid-lowering drugs and cancers: A drug target Mendelian randomization study","volume":"103","author":"Ding","year":"2024","journal-title":"Medicine"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Wang, W., Li, W., Zhang, D., Mi, Y., Zhang, J., and He, G. (2024). The Causal Relationship between PCSK9 Inhibitors and Malignant Tumors: A Mendelian Randomization Study Based on Drug Targeting. Genes, 15.","DOI":"10.3390\/genes15010132"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"16859","DOI":"10.1002\/cam4.6310","article-title":"Effect of proprotein convertase subtilisin\/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trials","volume":"12","author":"Mohammadi","year":"2023","journal-title":"Cancer Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"101043","DOI":"10.1016\/j.tranon.2021.101043","article-title":"Influence of cholesterol on cancer progression and therapy","volume":"14","author":"Mayengbam","year":"2021","journal-title":"Transl. Oncol."},{"key":"ref_10","first-page":"257","article-title":"Dyslipidemia and colorectal cancer risk: A meta-analysis of prospective studies","volume":"26","author":"Yao","year":"2015","journal-title":"Cancer Causes Control"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1586\/era.12.75","article-title":"Dyslipidemia, statins and prostate cancer","volume":"12","author":"Rice","year":"2012","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s12944-018-0925-z","article-title":"Dyslipidemia and non-small cell lung cancer risk in Chinese population: A case-control study","volume":"17","author":"Hao","year":"2018","journal-title":"Lipids Health Dis."},{"key":"ref_13","first-page":"778","article-title":"Lipid metabolism and carcinogenesis, cancer development","volume":"8","author":"Long","year":"2018","journal-title":"Am. J. Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Bhattacharya, A., Chowdhury, A., Chaudhury, K., and Shukla, P.C. (2021). Proprotein convertase subtilisin\/kexin type 9 (PCSK9): A potential multifaceted player in cancer. Biochim. Biophys. Acta Rev. Cancer, 1876.","DOI":"10.1016\/j.bbcan.2021.188581"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Wang, R., Liu, H., He, P., An, D., Guo, X., Zhang, X., and Feng, M. (2022). Inhibition of PCSK9 enhances the antitumor effect of PD-1 inhibitor in colorectal cancer by promoting the infiltration of CD8(+) T cells and the exclusion of Treg cells. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.947756"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41586-020-2911-7","article-title":"Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer","volume":"588","author":"Liu","year":"2020","journal-title":"Nature"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1038\/s41467-022-31663-z","article-title":"The cholesterol uptake regulator PCSK9 promotes and is a therapeutic target in APC\/KRAS-mutant colorectal cancer","volume":"13","author":"Wong","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1593\/neo.121252","article-title":"Proprotein convertase subtilisin\/kexin type 9 deficiency reduces melanoma metastasis in liver","volume":"14","author":"Sun","year":"2012","journal-title":"Neoplasia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"20587384211038345","DOI":"10.1177\/20587384211038345","article-title":"Pro-protein convertase subtilisin\/kexin type 9 promotes intestinal tumor development by activating Janus kinase 2\/signal transducer and activator of transcription 3\/SOCS3 signaling in Apc(Min\/+) mice","volume":"35","author":"Yang","year":"2021","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jjcc.2017.11.013","article-title":"Effect of alirocumab on coronary atheroma volume in Japanese patients with acute coronary syndromes and hypercholesterolemia not adequately controlled with statins: ODYSSEY J-IVUS rationale and design","volume":"71","author":"Ako","year":"2018","journal-title":"J. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.amjcard.2015.02.006","article-title":"Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin\/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia","volume":"115","author":"Ballantyne","year":"2015","journal-title":"Am. J. Cardiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","article-title":"A 52-week placebo-controlled trial of evolocumab in hyperlipidemia","volume":"370","author":"Blom","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1016\/j.jacc.2020.03.025","article-title":"Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study","volume":"75","author":"Boccara","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","article-title":"Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: The ODYSSEY COMBO II randomized controlled trial","volume":"36","author":"Cannon","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.atherosclerosis.2015.11.010","article-title":"Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial","volume":"244","author":"Farnier","year":"2016","journal-title":"Atherosclerosis"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1161\/CIRCULATIONAHA.121.057807","article-title":"Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab","volume":"146","author":"Steg","year":"2022","journal-title":"Circulation"},{"key":"ref_27","first-page":"2996","article-title":"ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia","volume":"36","author":"Kastelein","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.ahj.2015.03.004","article-title":"Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study","volume":"169","author":"Kereiakes","year":"2015","journal-title":"Am. Heart J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jacl.2017.09.007","article-title":"A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT)","volume":"12","author":"Koh","year":"2018","journal-title":"J. Clin. Lipidol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1161\/CIRCULATIONAHA.113.007012","article-title":"Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial","volume":"129","author":"Koren","year":"2014","journal-title":"Circulation"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease","volume":"387","author":"Rosenson","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jacl.2020.01.001","article-title":"Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: Open-label treatment period of the ODYSSEY ALTERNATIVE trial","volume":"14","author":"Moriarty","year":"2020","journal-title":"J. Clin. Lipidol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"Jama"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.jcmg.2022.03.002","article-title":"Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction","volume":"15","author":"Nicholls","year":"2022","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","article-title":"Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial","volume":"315","author":"Nissen","year":"2016","journal-title":"Jama"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1111\/dom.13257","article-title":"Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial","volume":"20","author":"Ray","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","article-title":"Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients","volume":"376","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJMoa1614062","article-title":"Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab","volume":"376","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/S0140-6736(12)61770-X","article-title":"Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): A randomised, placebo-controlled, dose-ranging, phase 2 study","volume":"380","author":"Giugliano","year":"2012","journal-title":"Lancet"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1701131","article-title":"Cognitive Function in a Randomized Trial of Evolocumab","volume":"377","author":"Giugliano","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.atherosclerosis.2016.08.043","article-title":"A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I","volume":"254","author":"Roth","year":"2016","journal-title":"Atherosclerosis"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1161\/JAHA.116.003421","article-title":"Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study","volume":"5","author":"Stroes","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12944-017-0513-7","article-title":"Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale","volume":"16","author":"Teramoto","year":"2017","journal-title":"Lipids Health Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1253\/circj.CJ-16-0387","article-title":"Efficacy and Safety of Alirocumab in Japanese Patients With Heterozygous Familial Hypercholesterolemia or at High Cardiovascular Risk With Hypercholesterolemia Not Adequately Controlled With Statins\u2014ODYSSEY JAPAN Randomized Controlled Trial","volume":"80","author":"Teramoto","year":"2016","journal-title":"Circ. J."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12944-020-01280-0","article-title":"Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a)","volume":"19","author":"Zhang","year":"2020","journal-title":"Lipids Health Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jacl.2019.10.015","article-title":"ODYSSEY EAST: Alirocumab efficacy and safety vs ezetimibe in high cardiovascular risk patients with hypercholesterolemia and on maximally tolerated statin in China, India, and Thailand","volume":"14","author":"Han","year":"2020","journal-title":"J. Clin. Lipidol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3892\/ijmm.2012.1072","article-title":"PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-\u03baB activation in THP-1-derived macrophages","volume":"30","author":"Tang","year":"2012","journal-title":"Int. J. Mol. Med."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Alannan, M., Seidah, N.G., and Merched, A.J. (2022). PCSK9 in Liver Cancers at the Crossroads between Lipid Metabolism and Immunity. Cells, 11.","DOI":"10.3390\/cells11244132"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s41392-024-01929-7","article-title":"Sex difference in human diseases: Mechanistic insights and clinical implications","volume":"9","author":"Shi","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.canlet.2019.08.017","article-title":"Sex disparities in cancer","volume":"466","author":"Zhu","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/s41568-021-00348-y","article-title":"Sex disparities matter in cancer development and therapy","volume":"21","author":"Haupt","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc.2016.30","article-title":"Sexual dimorphism in cancer","volume":"16","author":"Clocchiatti","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_60","first-page":"105","article-title":"On the sex ratio of all-cause and disease-specific mortality rates worldwide","volume":"69","author":"Kesteloot","year":"2007","journal-title":"Verh. K. Acad. Geneeskd. Belg."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.envres.2006.09.007","article-title":"Social sexual inequality and sex difference in cancer incidence","volume":"104","author":"Benigni","year":"2007","journal-title":"Environ. Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/BF03324754","article-title":"Men: Good health and high mortality. Sex differences in health and aging","volume":"20","author":"Oksuzyan","year":"2008","journal-title":"Aging Clin. Exp. Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1158\/1055-9965.EPI-08-1118","article-title":"Sex disparities in cancer incidence by period and age","volume":"18","author":"Cook","year":"2009","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1038\/bjc.2015.70","article-title":"The significant survival advantage of female sex in nasopharyngeal carcinoma: A propensity-matched analysis","volume":"112","author":"OuYang","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1200\/JCO.2006.08.1455","article-title":"Sex differences in lung cancer survival: Do tumors behave differently in elderly women?","volume":"25","author":"Wisnivesky","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Jia, F., Fei, S.F., Tong, D.B., Xue, C., and Li, J.J. (2022). Sex difference in circulating PCSK9 and its clinical implications. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.953845"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.atherosclerosis.2020.07.014","article-title":"Sex-specific predictors of PCSK9 levels in a European population: The IMPROVE study","volume":"309","author":"Ferri","year":"2020","journal-title":"Atherosclerosis"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s12933-020-01185-3","article-title":"Association of circulating proprotein convertase subtilisin\/kexin type 9 levels and the risk of incident type 2 diabetes in subjects with prediabetes: A population-based cohort study","volume":"19","author":"Shi","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Zhang, Z., Wei, T.F., Zhao, B., Yin, Z., Shi, Q.X., Liu, P.L., Liu, L.F., Liu, L., Zhao, J.T., and Mao, S. (2019). Sex Differences Associated With Circulating PCSK9 in Patients Presenting With Acute Myocardial Infarction. Sci. Rep., 9.","DOI":"10.1038\/s41598-018-35773-x"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/pedi.12490","article-title":"Obesity and type 2 diabetes are associated with elevated PCSK9 levels in young women","volume":"18","author":"Levenson","year":"2017","journal-title":"Pediatr. Diabetes"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Wang, S., Cowley, L.A., and Liu, X.S. (2019). Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and Therapeutic Strategy. Molecules, 24.","DOI":"10.3390\/molecules24183214"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ccell.2022.06.005","article-title":"Sex and cancer immunotherapy: Current understanding and challenges","volume":"40","author":"Pala","year":"2022","journal-title":"Cancer Cell"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S1470-2045(18)30261-4","article-title":"Cancer immunotherapy efficacy and patients\u2019 sex: A systematic review and meta-analysis","volume":"19","author":"Conforti","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1111\/dom.13114","article-title":"Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial","volume":"19","author":"Leiter","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ahj.2014.07.028","article-title":"Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY outcomes trial","volume":"168","author":"Schwartz","year":"2014","journal-title":"Am. Heart J."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.122.061620","article-title":"Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease","volume":"146","author":"Giugliano","year":"2022","journal-title":"Circulation"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","article-title":"Anti-PCSK9 monotherapy for hypercholesterolemia: The MENDEL-2 randomized, controlled phase III clinical trial of evolocumab","volume":"63","author":"Koren","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1001\/jama.2014.4030","article-title":"Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: The LAPLACE-2 randomized clinical trial","volume":"311","author":"Robinson","year":"2014","journal-title":"Jama"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/8\/1095\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:15:02Z","timestamp":1760033702000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/8\/1095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":80,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["ph18081095"],"URL":"https:\/\/doi.org\/10.3390\/ph18081095","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]}}}